• Home
• About us
• Investor
• Press
• Support
• Jobs

Press release

• Financial information
• Linköping Sweden
• April 6 , 2004

Not for distribution in the US or Canada

Sectra increases investment in MicroDose Mammography and explores potential for financing via a private placement of new shares

Sectra is planning to increase its investment in the mammography area. By allocating substantial resources for market investments, Sectra will be able to establish itself more rapidly as a leading player in mammography screening through the unique Sectra MicroDose Mammography system.

To finance the investment, Sectra is considering implementing a private placement of new shares supported by the mandate given to the Company's Board of Directors at the Annual General Meeting in June 2003. Sectra has commissioned Hagströmer & Qviberg to explore the market conditions for such a placement. If implemented, the new issue could also lead to a broadened institutional ownership. Sectra's ownership base is currently dominated by the company's founders and employees, who combined own about 60% of the share capital. A total of about 20% of Sectra's share capital is accounted institutional owners.

Sectra MicroDose Mammography

The Sectra MicroDose Mammography is a digital mammography system that is based on a completely new digital detector technology. This technology makes it possible to combine very high image quality with significantly reduced radiation doses. The main advantages associated with Sectra MicroDose Mammography are that the radiation dose can be reduced by 80% compared with film-based systems, and the unique productivity that allows examination of up to 70 patients per day. The system is developed in cooperation with jointly owned Mamea Imaging AB and is patent-protected.

Helsingborg Hospital in Sweden is the first mammography department to use Sectra MicroDose Mammography in clinical operations. The system was installed in September 2003 and more than 5,000 women have subsequently been screened using the new system. The successful results noted by Helsingborg Hospital are important confirmation that the system functions in a clinical environment.

The mammography market

Mammography screening is the second most common radiology examination in the world. An estimated approximately 30,000 conventional systems are installed in the market and it is expected that these will be replaced at a rate of about 4,500 systems per year. A high proportion of the new systems will be digital, which means there is significant potential for Sectra MicroDose Mammography in this area.

For further information, please contact:

Sectra AB, Dr. Jan-Olof Brüer, President and CEO,
+46 705 23 52 09, job/a/sectra/d/se

Downloads

Download this press release in Acrobat 4 Portable Document Format, PDF, nice for printing:

• English
• Svenska